Clinical outcomes from a community pharmacy feasibility study for the primary prevention of cardiovascular disease by McNamara, Kevin et al.
Clinical outcomes from a community pharmacy 
feasibility study for the primary prevention of 
cardiovascular disease
Authors: Mc Namara K,1,2 Peterson G,3 George J,1 Jackson S,3 Howarth H,3
O'Reilly S,5 Dunbar JA,2 Trinder P,1 Finch J,3 Bunker S,2 Janus E,2 Morabito L,1
Emery J,6 Duncan G,1 Bailey M.7
.
Conclusions
These findings suggest that pharmacists are capable of effectively managing multiple CVD risk factors. The overall relative risk
reduction is comparable with or exceeds results of any similar trials identified in any setting, and provides justification for the collection 
of more evidence through a larger, randomised controlled trial.
Results
Participants (female 73%, male 27%) had an overall mean age of 60 years and an average of 4.1 chronic conditions. Table 1 presents 
the baseline CVD risk and changes to CVD risk. An absolute risk reduction of 1.66% was observed, equivalent to a relative risk reduction 
of 24.4 +/- 9.3%. Improved clinical outcomes were accompanied by significant improvements to medicines adherence and several 
aspects of lifestyle modification.
Aim of study
To measure the HHIP program effectiveness in reducing patients’ cardiovascular risk. 
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Background
Despite the huge societal burden of cardiovascular disease (CVD), few healthcare programs address its primary prevention holistically. ‘Healthy Hearts in Pharmacy’ (HHIP), a 
pilot program, was implemented in 10 community pharmacies to provide a comprehensive, patient-centred program for reduction in the primary onset of CVD through medicines 
use optimisation and lifestyle modification.
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Table 1.  Changes to overall cardiovascular risk and key individual CVD risk factors*
Overall 
(0 mths)
Overall
(6 mths)
Change in outcome** P
N 70 67 67
Overall cardiovascular risk scores
Mean  5-year CVD risk* (%) 6.66 +/- 1.06 4.1 (2.5-7.0)* -1.66 (0.32) <0.001
Key modifiable score components* 
Mean (SE) total cholesterol (mmol/L) 4.94 (0.113) 4.78 (0.11) -0.16 (0.10) 0.09
Mean (SE) HDL cholesterol (mmol/L) 1.28 (0.05) 1.30 (0.05) +0.02 (-0.17, 0.21)∞ 0.43
Mean (SE) total: HDL cholesterol ratio 4.37 (0.26) 3.92 (0.14) -0.20 (-0.77,0.39)∞ 0.04
Mean (SE) systolic BP (mmHg) 136.62 (2.46) 126.45 (15.68) -7 (-18.5, -1)∞ <0.001
Mean (SE) diastolic BP (mmHg) 85.52 (1.30) 80.77 (9.50) -4.98 (1.079) <0.001
Proportion currently smoking 9 6 0 (0,0)∞ 0.5
* Overall CVD risk (% risk of CVD event in 5 years) calculated using the New Zealand CVD risk equations1.
∞ Non-parametric test was the more appropriate statistic owing to data distribution.
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Figure 1. The HHIP 
patient intervention
The intervention process
Pharmacists from 10 pharmacies recruited a convenience sample of 70 patients aged 50–74 yrs, free from CVD or diabetes and receiving 
medication for hypertension or a lipid disorder. The intervention is described in Figure 1.
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